Hutchmed Projects Gain of $477 Million From Hutchison Pharmaceutical Stake Disposal

MT Newswires Live01-02

Hutchmed (China) (HKG:0013) expects to book a pre-tax gain of approximately $477 million after its wholly-owned subsidiary sold shares in Shanghai Hutchison Pharmaceuticals (SHP).

The disposal involved selling a 35% stake to GP Health Service Capital for approximately $473 million and a 10% stake to Shanghai Pharma (HKG:2607, SHA:601607) for around $135 million.

Before this transaction, SHPL, a joint venture operating its own-brand prescription drug business, was equally owned by Hutchmed's subsidiary and Shanghai TCM.

With the completion of this sale, Hutchmed will maintain a 5% indirect interest in SHPL.

Disposal proceeds will be used to bolster Hutchmed's core business operations and advance its antibody drug conjugate platform, according to a filing on Wednesday.

Hutchmed's shares gained over 3% in early trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2500991961?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-02 10:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2500991961","market":"fut","top_or_hot":-1,"title":"Hutchmed Projects Gain of $477 Million From Hutchison Pharmaceutical Stake Disposal","media":"MT Newswires Live","content":"<html><body><p> Hutchmed (China) (HKG:0013) expects to book a pre-tax gain of approximately $477 million after its wholly-owned subsidiary sold shares in Shanghai Hutchison Pharmaceuticals (SHP).</p><p>The disposal involved selling a 35% stake to GP Health Service Capital for approximately $473 million and a 10% stake to Shanghai Pharma (HKG:2607, SHA:601607) for around $135 million.</p><p>Before this transaction, SHPL, a joint venture operating its own-brand prescription drug business, was equally owned by Hutchmed's subsidiary and Shanghai TCM.</p><p>With the completion of this sale, Hutchmed will maintain a 5% indirect interest in SHPL.</p><p>Disposal proceeds will be used to bolster Hutchmed's core business operations and advance its antibody drug conjugate platform, according to a filing on Wednesday.</p><p>Hutchmed's shares gained over 3% in early trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hutchmed Projects Gain of $477 Million From Hutchison Pharmaceutical Stake Disposal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHutchmed Projects Gain of $477 Million From Hutchison Pharmaceutical Stake Disposal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-02 10:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hutchmed (China) (HKG:0013) expects to book a pre-tax gain of approximately $477 million after its wholly-owned subsidiary sold shares in Shanghai Hutchison Pharmaceuticals (SHP).The disposal involved...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0099","symbol_name":"上海本地重组","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2500991961","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500991961","pubTimestamp":1735783723,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hutchmed   expects to book a pre-tax gain of approximately $477 million after its wholly-owned subsidiary sold shares in Shanghai Hutchison Pharmaceuticals .The disposal involved selling a 35% stake to GP Health Service Capital for approximately $473 million and a 10% stake to Shanghai Pharma  for around $135 million.Before this transaction, SHPL, a joint venture operating its own-brand prescription drug business, was equally owned by Hutchmed's subsidiary and Shanghai TCM.With the completion of this sale, Hutchmed will maintain a 5% indirect interest in SHPL.Disposal proceeds will be used to bolster Hutchmed's core business operations and advance its antibody drug conjugate platform, according to a filing on Wednesday.Hutchmed's shares gained over 3% in early trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0099":"上海本地重组","00013":"和黄医药","BK0188":"融资融券","BK1587":"次新股","BK0187":"一线龙头","BK7095":"多种金属与采矿","SHP.AU":"South Harz Potash Ltd","BK1191":"制药","BK0175":"白马股","BK0184":"上海国资改革","BK0209":"零售","BK0183":"MSCI概念","BK0196":"行业龙头","BK0012":"证金概念","BK0097":"医药电商","BK0020":"浦东新区","SES.SI":"Shanaya","02607":"上海医药","BK0028":"国家队","BK1197":"保健护理产品经销商","BK1588":"回港中概股"},"translate_title":"和黄医药预计出售和黄药业股份将获得4.77亿美元收益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":0.9,"00013":1,"SHP.AU":1,"SES.SI":1,"02607":0.9},"content_text":"Hutchmed (China) (HKG:0013) expects to book a pre-tax gain of approximately $477 million after its wholly-owned subsidiary sold shares in Shanghai Hutchison Pharmaceuticals (SHP).The disposal involved selling a 35% stake to GP Health Service Capital for approximately $473 million and a 10% stake to Shanghai Pharma (HKG:2607, SHA:601607) for around $135 million.Before this transaction, SHPL, a joint venture operating its own-brand prescription drug business, was equally owned by Hutchmed's subsidiary and Shanghai TCM.With the completion of this sale, Hutchmed will maintain a 5% indirect interest in SHPL.Disposal proceeds will be used to bolster Hutchmed's core business operations and advance its antibody drug conjugate platform, according to a filing on Wednesday.Hutchmed's shares gained over 3% in early trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2500991961"}